ABBV vs COLL · P/E 81, rev $61.16B vs P/E 17, rev $181.9M
AbbVie Inc (ABBV) versus Collegium Pharmaceutical Inc (COLL) — a side-by-side from cached financials, not a winner call.
AbbVie Inc (ABBV) is a drug manufacturers - general company listed on US. It is led by Rob Michael.
Collegium Pharmaceutical Inc (COLL) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported ABBV revenue for 2025-12-31 was $61.16B. Net income was $4.23B. Revenue was up 305.0% from 2024-12-31 to 2025-12-31. ABBV currently screens at market cap $334.34B and trailing P/E 80.5.
Latest reported COLL revenue for 2024-12-31 was $181.9M. Net income was $69.2M. Revenue was up 14.2% from 2024-09-30 to 2024-12-31. COLL currently screens at market cap $1.12B and trailing P/E 16.8.
ABBV currently screens at market cap $334.34B and trailing P/E 80.5. COLL currently screens at market cap $1.12B and trailing P/E 16.8.
Not investment advice. Open the ABBV and COLL stock pages for the full models.
Not investment advice.